<DOC>
	<DOCNO>NCT00629447</DOCNO>
	<brief_summary>To determine safety prophylaxis Tinzaparin low molecular weight heparin primary brain tumor patient . 2 . To determine incidence deep venous thrombosis pulmonary embolism brain tumor patient receive Tinzaparin primary prophylaxis . 3 . To determine overall survival patient malignant glioma receive Tinzaparin . 4 . To determine bone density prophylactic Tinzaparin .</brief_summary>
	<brief_title>Innohep Prophylaxis Venous Thromboembolism Brain Tumor Patients</brief_title>
	<detailed_description>Many patient brain tumor develop thin bone weak bone , call osteoporosis . At baseline ( within 4 week enrollment onto study ) 12 month subject bone densitometry study ( DEXA-Scan ) test determine bone density ( measure strength thickness bone ) use x-ray technique . A single arm pilot trial perform newly diagnose pathologically confirm malignant glioma patient . The patient receive low molecular weight heparin ( Tinzaparin ) , begin least 48 hour craniotomy stereotactic biopsy , later four week recent surgery . The patient receive single daily subcutaneous injection Tinzaparin 4500 IU . The primary analysis conduct six month safety determine incidence clinically significant bleeding , ≥ grade III/IV CNS hemorrhage grade II hemorrhage elsewhere . The Tinzaparin discontinue grade II high hemorrhage , except CNS hemorrhage patient asymptomatic CNS hemorrhage see scan ( grade III ) study entry stay Tinzaparin , except CNS hemorrhage expand new hemorrhage , case Tinzaparin discontinue . For patient without CNS hemorrhage entry , new asymptomatic CNS hemorrhage ( grade III ) , CNS hemorrhage symptom ( ≥ grade IV ) result discontinuation Tinzaparin . If patient hemorrhage , Tinzaparin continue additional six month second analysis perform 12 month . Patients may stay Innohep long benefit adverse reaction necessitation stop therapy . Patients continue labs clinical follow-up .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Patients newly diagnose pathologically confirm WHO Grade III Grade IV glioma ( anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic mixed glioma , gliosarcoma glioblastoma multiforme ) ; 2 . Patients must 18 year age old time informed consent ; 3 . Karnofsky performance status 60 % life expectancy least 6 month ; 4 . The patient least 48 hour craniotomy stereotactic biopsy later four week last surgical procedure ; 5 . Adequate hematologic function demonstrate laboratory value perform within 14 day : platelet count &gt; 100,000 , prothrombin time ( PT ) 1.2 x control , inactivate partial thromboplastin time ( aPTT ) 1.2 x control ; 6 . Signed informed consent prior patient registration . 1 . Presence coagulopathy , define laboratory parameter include platelet count &lt; 100,000 , PT &gt; 1.2 x control PTT &gt; 1.2 x control . 2 . Symptomatic intracranial bleeding , include inter intratumor bleed cause mass effect neurological disability control ; 3 . The presence acute chronic deep venous thrombosis demonstrate ultrasonography venography . A baseline screen ultrasound venogram require ; 4 . Active systemic bleeding , gastrointestinal bleeding gross hematuria ; 5 . Excessive risk bleeding define stroke within prior 6 month , history CNS intraocular bleed , septic endocarditis ; 6 . Prior history document DVT PE ; 7 . History immune mediate heparin induce thrombocytopenia , document platelet count &lt; 50,000 positive heparininduced platelet aggregation test ; 8 . Contraindication tinzaparin heparin , include allergy hypersensitivity heparin pork product , sulfite allergy , benzyl alcohol allergy epidural catheter traumatic spinal puncture within 7 day prior screen ; 9 . Serum creatinine &gt; 3.0 mg/dl ; 10 . Patient partner childbearing potential use adequate contraception ; 11 . Pregnant nursing ( woman childbearing potential may screen pregnancy test discretion investigator ) ; 12 . Medical condition require longterm anticoagulant atrial fibrillation mechanical heart valve ; 13 . Inability give informed consent ; 14 . Inability comply study procedure , include subcutaneous injection diagnostic procedure ; 15 . Participating another study investigational agent time enrollment . The use experimental investigational regimen approve product cause exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Primary Brain Tumor</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Heparin</keyword>
</DOC>